ClinicalTrials.gg
TerminatedNCT00199381Updated May 17, 2024Results posted

An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

A Phase 3 interventional study of Istradefylline in Parkinson's Disease, sponsored by Kyowa Kirin, Inc.. Terminated at 1 site in United States. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2024-05-17.

Sponsored by Kyowa Kirin, Inc. · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Additional long-term safety data no longer needed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
504
Allocation
Not applicable
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 20 studies testing istradefylline in Parkinson Disease — none open to participants now, none under way, none of them phase 3. istradefylline · Parkinson Disease.

Enrollment
4th of 19
504 · median 239
Started
2005
with 4 others
Phase 3
10 of 20
none open now
Registered
2nd of 20
by date
Lead sponsor
8 of 20
Kyowa Kirin, Inc.

Among the 20 studies testing istradefylline in Parkinson Disease, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2005, is one of 10 in phase 3, and was the 2nd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 20 studies testing istradefylline in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About istradefylline

istradefylline: first FDA approval 2019 (NOURIANZ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing istradefylline in Parkinson Disease as a file.
02

Study summary

This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.

Read the detailed description

Patients with Parkinson's disease with motor complications on levodopa therapy who completed the prior double-blind study 6002-INT-001 are eligible to enter into this long-term open safety study with a starting istradefylline dose of 20 or 40mg per day.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Parkinson's Disease
  • levodopa
  • end of dose wearing off
  • OFF time
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of study 6002-INT-001
  • Not of

Exclusion criteria

Exclusion Criteria:

  • Cancer within 5 years of enrollment
  • /AST levels > 2.5 times
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
504 participants (actual)

Study arms

  • Experimental
    Single Arm

    Treatment with oral istradefylline (KW-6002) 20 or 40 mg once daily.

    Drug: Istradefylline

Interventions

  • Oral istradefylline (KW-6002) 20 or 40 mg once daily.

    Also known as: KW-6002

06

What researchers measure

Primary outcomes

  1. Safety as Measured by Adverse Events

    Investigation of the long-term tolerability and safety of istradefylline

    Time frame: Every 2 months up to 32 months

07

Results

Posted Jul 30, 2013
Limitations and caveats
The Sponsor decided to terminate the study early (not for safety reasons); as a result 323 subjects discontinued early. Mean duration of therapy was 18.7 months (0.4 to 31.4 months); median duration was 21.0 months. Total exposure 767 subject years.

Participant flow

73 study centers in the US and Canada recruited subjects from the initiation date (28 October 2005). Patients who had previously participated in Study 6002-INT-001 were eligible to participate in this follow-on safety study,and hence had been taking istradefylline for at least a year.

Participant flow — Overall Study
MilestoneSingle Arm
Started504
Completed0
Not completed504
Withdrew: Withdrawal by subject38
Withdrew: Adverse event73
Withdrew: Protocol violation6
Withdrew: Lack of efficacy27
Withdrew: Not including due to early termination37
Withdrew: Study termination by sponsor323

Outcome measures

PrimarySafety as Measured by Adverse Events

Investigation of the long-term tolerability and safety of istradefylline

Time frame:
Every 2 months up to 32 months
Reported as:
Number · participants
Safety as Measured by Adverse Events
participantsSingle Arm
Safety as Measured by Adverse Events477

Adverse events

Collected over Dosing to end of treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Arm—201/503 (40%)276/503 (54.9%)
Most frequent serious events
Showing 10 of 174
Most frequent serious events
EventSingle Arm
Parkinson's diseaseNervous system disorders51/503
Confusional statePsychiatric disorders10/503
AccidentInjury, poisoning and procedural complications9/503
SyncopeNervous system disorders8/503
Hip fractureInjury, poisoning and procedural complications8/503
PneumoniaInfections and infestations8/503
Localised osteoarthritisMusculoskeletal and connective tissue disorders6/503
OsteoarthritisMusculoskeletal and connective tissue disorders6/503
Myocardial infarctionCardiac disorders6/503
Cervical spinal stenosisMusculoskeletal and connective tissue disorders5/503
Most frequent other events
Showing 10 of 25
Most frequent other events
EventSingle Arm
Parkinson's diseaseNervous system disorders151/503
DyskinesiaNervous system disorders136/503
AccidentInjury, poisoning and procedural complications102/503
HallucinationPsychiatric disorders69/503
ArthralgiaMusculoskeletal and connective tissue disorders63/503
DepressionPsychiatric disorders54/503
ConstipationGastrointestinal disorders49/503
InsomniaPsychiatric disorders49/503
Urinary tract infectionInfections and infestations47/503
Back painMusculoskeletal and connective tissue disorders46/503

Baseline characteristics

503 subjects took at least 1 dose of study drug

Age, Categorical
Age, Categorical(Participants)Single Arm
<=18 years0
Between 18 and 65 years244
>=65 years259
Age, Continuous
Age, Continuous(years)Single Arm
Mean64.5 ± 8.98
Sex: Female, Male
Sex: Female, Male(Participants)Single Arm
Female155
Male348
Region of Enrollment
Region of Enrollment(participants)Single Arm
United States401
Canada102
08

Study locations

1 site
  • Kyowa Pharmaceutical Inc.
    Princeton, New Jersey 08540, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 4 years 9 months after primary completion. A results delay was requested in Apr 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 20, 2005
Start
Oct 2005
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results delay requested
Apr 4, 2011
Results first posted
Jul 30, 2013
Last update
May 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00199381
Lead sponsor
Kyowa Kirin, Inc.
Responsible party
Sponsor
First posted
Sep 20, 2005
Start date
Oct 2005
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Jul 30, 2013
Last update
May 17, 2024

Study contacts

Neil Sussman, MD
study director · Kyowa Kirin, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Istradefylline

Start the discussion